Policy | August 27, 2025
GST rejig may impact competitiveness of medical devices: AiMeD
AiMeD noted that proposed GST changes—to either 5% or 18%—both present significant risks requiring carefully nuanced consideration
AiMeD noted that proposed GST changes—to either 5% or 18%—both present significant risks requiring carefully nuanced consideration
This achievement is part of the population-based initiative for screening, prevention, and management of Non-Communicable Diseases
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
Milestone also announced the extension of its $75 million Royalty Purchase Agreement with RTW Investments
The freshly infused capital will primarily be deployed towards expansion and research & development
These appointments align with the group’s philosophy of having a strong and independent board with exceptional industry experts, ensuring strategic guidance and effective governance
Expand the scope of the Production-Linked Incentive (PLI) scheme and increase its allocation to cover more pharmaceutical products and raw materials
40th DSIR Foundation Day celebration marks 16 more technology transfers from CSIR to MSMEs
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
The transaction is expected to result in approximately $175 million to support further development of IMG-007
Subscribe To Our Newsletter & Stay Updated
